AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Oncolytics Biotech shares surge 19.62% after-hours after announcing FDA engagement for pancreatic cancer trial plans.
ByAinvest
Wednesday, Jan 21, 2026 5:25 pm ET1min read
ONCY--
Oncolytics Biotech (ONCY) surged 19.62% in after-hours trading, driven by Lake Street Capital initiating coverage with a "Buy" recommendation on August 14, 2025, and the company regaining Nasdaq compliance on July 22, 2025. The stock also gained momentum following presentations of Pelareorep’s clinical data at key opinion leader events in July, highlighting its potential in pancreatic and gastrointestinal cancers. These developments addressed prior regulatory concerns and reinforced investor confidence in the company’s pipeline advancements, aligning with the significant after-hours price rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet